Optimizing Outcomes: Multidisciplinary Management of Advanced Bladder Cancer

Access Course


902370.jpg?interpolation=lanczos-none&resize=300:*Drs Milowsky and Smith discuss the evolving use of checkpoint inhibition in patients with advanced bladder cancer.


This activity is intended for oncologists, urologists, nurses, and other healthcare professionals who treat patients with bladder cancer.


The goal of this activity is to discuss the most up-to-date use of immunotherapy in the treatment of patients with advanced bladder cancer.



Approximate Time to Complete: 30 minutes


Credit Available: Sep. 27, 2018- Sep. 27, 2019


Developed through a partnership between SITC and Medscape.

sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
Course Objectives
Upon completion of this activity, participants will be able to:
  • Have increased knowledge regarding the individual roles of multidisciplinary medical cancer care team members in the treatment of patients with advanced bladder cancer
  • Have greater competence related to appropriate use of cancer immunotherapies across the continuum of care for patients with advanced bladder cancer
American Nurses Credentialing Center's Commission on Accreditation
Contact Hour: 0.50
American Board of Internal Medicine
ABIM MOC Part 2 Credits: 0.50
(0.5 contact hours are in the area of pharmacology)
Accreditation Council for Continuing Medical Education (MD/DO)
AMA PRA Category 1 Credit(s)™: 0.50